Primary findings show Chinese COVID-19 vaccine candidate safe

Henrietta Brewer
October 17, 2020

Sputnik V, an adenovirus vector-based vaccine, was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund and registered on August 11.

The draft of the implementation plan drawn by the national expert group on vaccine administration for Covid-19 has worked on inputs received by central agencies and the states. Worldwide, about 40 vaccine candidates are in the race of vaccination. It is now undergoing phase 3 clinical trial in Russian Federation, with the developers planning to enroll 40,000 participants.

The vaccine from Sinovac is also in the late-stage trials in Indonesia, Brazil, and Turkey and the company has stated that an interim analysis of the Phase 3 trial data might come as early as November.


Chinese President Xi Jinping has also previously declared that Chinese vaccines would be made a "global public good". More on Covid-19Dr Reddy's co-chairman and managing director G V Prasad termed it as a significant development that will allow the company to commence the clinical trials for Sputnik V in India. Although 55 per cent of the population is below 50 years of age, yet, as per the availability of vaccines, healthcare workers should get the vaccines first, then people over 60 years of age with comorbidities followed by the rest of the populace.

Is there hope for the world to see a vaccine at the end of 2020?

"The prime minister further directed that we should make use of experience of successful conduct of elections and disaster management in the country".


Two injections of BBIBP-CorV at three different doses generated antibodies in all recipients of each group, including older participants, although the data does not prove the vaccine is efficacious, researchers at the CNBG subsidiary, Chinese disease control authorities and other research institutes said in the paper. However, the biggest challenge lies in its accessibility.

We need to talk about vaccines; we need to vaccinate enough people - protection and protection can be accomplished safely with a vaccine.

Elaborating on the status of the vaccine development, Samir Deb, Pharmaceutical Professional, Consultant Vaccine & Public Affairs Consultant, South East Asia, said, "Vaccine development is a burning issue across the world now".


Vaccine misinformation expert Professor Heidi Larson said she feared that people's concerns about vaccine safety were not being addressed, which could result in them not taking it.

Other reports by iNewsToday

FOLLOW OUR NEWSPAPER